Evaluation Of Serum Magnesium, Calcium and Phosphorus in Female Patients Diagnosed with Menstrual Disorders
Keywords:
Mineral Profile, Menorrhagia, Hyperandrogenism, Menstrual Bleeding, Menstrual cycleAbstract
Introduction: Every healthy woman after attaining puberty undergo hormonal changes, go through menstruation cycle every month which involves the coordination of many events by the hypothalamus, pituitary, ovarian axis and is readily influenced by physiological, pathological and psychological changes occurring during the reproductive lifespan. They suffer from various menstrual disorders and their proper nutritional management is necessary. Levels of Serum Magnesium, Calcium and phosphorus may play important role in symptoms of these disorders.
Aim: To evaluate the levels of serum Magnesium, Calcium and Phosphorus levels among female patients diagnosed with menstrual disorders.
Material and Method: In the present case control study, serum Magnesium, Calcium and Phosphorus levels were determined in 100 Female Patient’s diagnosed for menstrual disorders i.e Abnormal uterine bleeding or AUB, PCOS and Dysmenorrhea, visiting the outpatient department (OPD) of gynecology fulfilling the inclusion criteria and exclusion criteria were enrolled for the study. Healthy females with a regular menstrual cycle constituted the control group. Inclusion criteria for the study were Females who were suffering from Abnormal uterine bleeding (AUB), Polycystic ovary syndrome (PCOS) and Dysmenorrhea between 18- 45 years of age and who were interested in taking part in the study. Females with Age below 18 and above 45 years, who are on drugs or hormone therapy, had an IUCD (intrauterine contraceptive device) were known to have cervical or uterine malignancy, fibromyoma etc. and Pregnant women were excluded from the study. Blood samples were collected by venipuncture using standard aseptic technique and following investigation were performed. Serum Calcium, Magnesium, Phosphorus by potentiometry using micro slide assay method on VITROS 5600.
Result: A total of 100 females diagnosed with Polycystic Ovary Syndrome (PCOS), Dysmenorrhea, and Abnormal Uterine Bleeding (AUB) were included in the study. The mean age was comparable between the control and patient groups for AUB and Dysmenorrhea, while the PCOS group had a relatively lower mean age (23.63 ± 4.50 years). The mean serum calcium level was 8.40 ± 1.76 mg/dL in the AUB group (P = 0.002), 8.23 ± 1.55 mg/dL in the PCOS group (P < 0.001), and 8.75 ± 1.72 mg/dL in the Dysmenorrhea group, with overall statistical significance (P = 0.063). The mean serum magnesium level was 2.61 ± 1.02 mg/dL in the AUB group (P < 0.001), 2.33 ± 0.82 mg/dL in the PCOS group (P < 0.001), and 2.88 ±
1.07 mg/dL in the Dysmenorrhea group (P < 0.001). Mean serum phosphorus levels were
5.28 ± 1.39 mg/dL in the AUB group (P < 0.001), 5.43 ± 1.64 mg/dL in the PCOS group (P < 0.001), and 5.21 ± 1.54 mg/dL in the Dysmenorrhea group (P < 0.001)
.
Conclusion: Levels of Calcium, phosphorus and Magnesium play a vital role in muscle function and hormonal regulation. They both play important role in healthy menstrual cycle. Imbalance of these minerals could contribute to menstrual abnormalities. Mean Calcium level was found to be decreased in patients with menstrual disorders whereas Mean Phosphorus levels and Magnesium levels increased in patient with menstrual disorders.
Downloads
References
Flug D, Largo RH, Prader A. Menstrual patterns in adolescent Swissgirls: a longitudinal study. Ann Hum Biol. 1984 ;11(6):495-508.
Presser HB. Temporal data relating to the human menstrual cycle. In:Ferin M, Halber F, Richart RM, et al., editors. Biorhythms and humanreproduction. New York: Wiley. 1974: 145-160.
Susan A. Calcium supplementation in postmenopausal women.Women’s Health. 2003:8(2);15-22.
Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO Working Groupon Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:313.
Franks S. Polycystic ovary syndrome. N Engl J Med. 1995; 333:853-861
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7:219–231.
Bowen DJ, Grunberg NE. Variations in food preference andconsumption across the menstrual cycle. Physiol Behave. 1990;47:243-252.
Johnson PE, Lykken GI. Manganese and calcium absorption & balance in young women feed diets with varying amounts at manganese and calcium. J Trace Elements Exp Med. 1991;4:19-35.
Bertone-Johnson ER, Hankinson SE, Bendich A, et al. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med. 2005;165(11):1246–1252. [PubMed] [Google Scholar]
Chocano Bedoya P, Manson J, Hankinson S, et al. Dietary B vitamin intake and incident premenstrual syndrome. Am J Clin Nutr. 2011;93(5):1080–1086. [PMC free article] [PubMed] [Google Scholar]
Das K, Chowdhury AR. Metallic ion concentration during menstrual cycle in normally menstruating women. Indian J Med Sci. 1997;51(2):52–54. [PubMed] [Google Scholar]
Posaci C, Erten O, Uren A, et al. Plasma copper, zinc and magnesium levels in patients with premenstrual tension syndrome. Acta Obstet Gynecol Scand. 1994;73(6):452–455. [PubMed] [Google Scholar]
Chuong CJ, Dawson EB. Zinc and copper levels in premenstrual syndrome. Fertil Steril. 1994;62(2):313–320. [PubMed] [Google Scholar]
Rosenstein DL, Elin RJ, Hosseini JM, et al. Magnesium measures across the menstrual cycle in premenstrual syndrome. Biol Psychiatry. 1994;35(8):557– 561. [PubMed] [Google Scholar]
Quaranta S, Buscaglia MA, Meroni MG, et al. Pilot study of the efficacy and safety of a modified-release magnesium 250 mg tablet (Sincromag) for the treatment of premenstrual syndrome. Clin Drug Investig. 2007;27(1):51–58. [PubMed] [Google Scholar]
Khine K, Rosenstein D, Elin R, et al. Magnesium (mg) retention and mood effects after intravenous mg infusion in premenstrual dysphoric disorder. Biol Psychiatry. 2006;59(4):327–333. [PMC free article] [PubMed] [Google Scholar]
Walker A, De Souza MC, Marakis G, et al. Unexpected benefit of sorbitol placebo in Mg intervention study of premenstrual symptoms: implications for choice of placebo in RCTs. Med Hypotheses. 2002;58(3):213–220. [PubMed] [Google Scholar]
Reeves BD, Garvin JE, McElin TW. Premenstrual tension: symptoms and weight changes related to potassium therapy. Am J Obstet Gynecol. 1971;109(7):1036–1041. [PubMed] [Google Scholar]
Pandya AK, Chandwani S, Das TK, Pandya KD. Serum Calcium Magnesium and Inorganic Phosphorous Levels during various Phases of Menstrual Cycle. Indian J Physiol Pharmacol. 1995;39:411-414.
Young DS. Phosphorus Metabolism. Clin Chem. 1975;21:342
Grober U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients. 2015;7(9):8199-8226.
Patricia M, Dolev E, Bernier LL. Magnesium and zinc status during menstrual cycle. Am J ObstetGynaecol. 1987;157:964-968.
Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2001;(3):8-12.
Penland JG, Johnson PE. Dietary calcium and manganese effects on menstrual cycle symptoms. Am J Obstet Gynecol. 1993;168(5):1417- 1423
Langley WF, Mann D. Central nervous system magnesium deficiency. Arch Intern Med. 1991;151(3):593-596.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
